Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + famitinib versus platinum-based chemotherapy for recurrent or metastatic cervical cancer
CTR20211227Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, famitinib in Cervical Cancer (CC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Aug 2021; status: active.
02
Drugs
camrelizumabfamitinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20211227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211227.